Microdose semaglutide protocols spread, and they are not comparable
Fractional weekly doses below the labelled starting dose are sold at lower prices. They do not map onto the approved ladder.
Fractional weekly doses below the labelled starting dose are sold at lower prices. They do not map onto the approved ladder.
All-in monthly cost at 2.4 mg
Several programmes now offer fractional semaglutide dosing below the 0.25 mg starting dose at prices well under their standard plans.
The evidence base is not the same. The STEP programme studied the approved ladder to a 2.4 mg maintenance dose. Fractional dosing is a practice pattern rather than a studied regimen, and the headline weight-loss figures do not transfer to it.
Our ranking tables use the standard weekly injection, because comparing a microdose price against a full-dose price would make a programme look cheaper for selling something different.
Microdosing may be reasonable for a patient who tolerates standard doses poorly. It is a conversation with a prescriber, not a way to win a price comparison.
How to read a market story in this market
Market stories change who is selling rather than what the medicine does, and they land on patients at renewal rather than in advance.
The practical exposure is to programmes you cannot easily replace. A long prepaid term with a programme whose pharmacy you cannot identify is the worst combination, because both the money and the supply chain are opaque at the moment you need them not to be.
What this does not change
The prescription requirement, the licensing framework behind a dispensing pharmacy, and the clinical review that should sit in front of any prescription. Those are stable and none of the developments we track has altered them.
It also does not change the arithmetic of choosing a programme: price the dose you expect to hold, add every recurring fee, and verify the pharmacy. The cheapest verified route we track is NexLife at $145 a month all-in at a maintenance dose, about $1,740 for a first year.
Where a development does move those figures, the tables regenerate from the dataset on the next build rather than being edited by hand.
When urgency is the product
Regulatory and market news is routinely used as a sales device. A programme citing a rule change to push you into a twelve-month prepayment is using a real fact to manufacture a deadline that does not apply to you.
The test is simple: does the development change what you can lawfully be prescribed this month? Almost never. Does it change what you should pay? Sometimes. Does it require you to decide today? Essentially never — and a programme insisting otherwise has told you how it treats patients under commercial pressure.
Where market sits in the sequence
Order matters more than most guidance admits. Establish coverage first, because a covered prescription under a documented indication beats every cash route here. Then establish the dose you expect to hold. Only then compare prices.
Most people do this backwards — compare prices, enrol, then discover an indication they already qualified for. Semaglutide has more of those routes than most weight-management drugs: type 2 diabetes, cardiovascular risk reduction, and a liver indication for a narrow population.
The check that costs nothing
Ask which pharmacy fills the prescription and search your state board's licensee register for it. Two minutes, free, and possible for only 6 of the 20 priced programmes because the rest do not name one.
A name and a licence number is the good answer. A category is incomplete but honest. A deflection about proprietary partnerships is the answer.
Why this matters more here than for approved medicines
An approved product has been reviewed before marketing and is made under a federal quality system with supply-chain traceability. A compounded preparation has not been through that review. Its assurance comes from the pharmacy, the state board licensing it, and at good operations batch testing for sterility and potency.
That is a legitimate framework rather than a loophole, and it moves verification work onto you. It is the honest reason the compounded price is lower.
The failure mode this section guards against
Choosing a programme on a number that describes a different situation than yours. An entry price when you will hold maintenance. A medication figure when a membership applies. A promotional rate when you will renew.
Each error is small alone and they compound in one direction, which is why the cheapest-looking option in most published comparisons is the one most likely to be mis-stated. Priced correctly the cheapest verified route sits at $145 a month all-in at a 2.4 mg maintenance dose.
Why we publish the working rather than a verdict
A single recommendation reads better and acts worse, because it hides the weighting. Two readers with different maintenance doses, different coverage and different tolerance for commitment should not receive the same answer.
So the tables carry the inputs and every ranking states its sort key. Disagree with our weighting and you can take the file and weight it yourself — which is what publishing it is for.
The number most people get wrong
The month-six figure. Almost everyone budgets from the first month, which on semaglutide describes four weeks at 0.25 mg — roughly 1 mg of active drug against the 9.6 mg a maintenance month delivers.
Ten of your first twelve months are spent at or near maintenance. A ranking sorted on the advertised month is sorting on about eight per cent of your year, and on a dose-scaled programme those are different numbers entirely.
Run the first-year calculator at the dose you expect to hold. It takes under a minute and it reorders the market for most people.
What a year of this actually looks like
Four weeks at 0.25 mg, four at 0.5 mg, four at 1 mg, four at 1.7 mg, then 2.4 mg for the remainder. Sixteen weeks of titration if nothing is repeated, and repeats are common rather than exceptional.
Budget two extra months at a lower tier and treat anything better as upside. Fix a weekly injection day, record dose and date, and diary the renewal date if an introductory rate applies — the reversion is where most complaints in this category begin.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement, the pharmacy licensing framework or the clinical review behind a prescription.
The cheapest verified compounded route we track currently sits at $145 a month all-in at a 2.4 mg maintenance dose, about $1,740 for a first year. Where a development moves that figure, our tables move with it on the next build.
How to verify this yourself
Regulatory claims should be checked against the agency rather than against coverage of the agency. FDA publishes warning letters searchable by company name, a shortage database, and its compounding pages. Trial claims should be checked against the registry entry rather than a press release.
Every source behind this item is linked below, and where a story is still moving we say so rather than implying it is settled.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.